MIAMI — Burger King is testing menu items like Whopper Bites and protein-forward bowls. The chain is adjusting its product offerings in response to shifting consumer habits linked to the use of GLP-1 weight-loss medications.

King president of U.S. and Canada Tom Curtis said he anticipates significant changes in the sector, adding, 'My impulse has always been that this GLP-1 movement is going to have a profound impact on the industry.'

He noted that the company has not yet observed a direct downturn in sales attributed to these medications, saying, 'We haven’t seen it yet, so I keep telling the team, Hey, we need to be prepared for this.'

The strategy involves offering customers options that align with different dietary needs while maintaining the core appeal of the brand. Curtis said, 'What’s important for us is that we have all of the variety and innovation available in a smaller package.'

He emphasized that the company would not rush to add permanent complexity to its operations without clear evidence of sustained customer demand, stating, 'We need the demand there before we really complexify, if you will, the menu, because simplicity is king in the fast food business.'

He rejected the notion that the fundamental appeal of quick-service restaurants is disappearing. When asked if the value proposition of fast food was becoming obsolete, he replied, 'Absolutely not.'

'Fast food is about convenience. It’s about great flavor and great value. I still think you need that,' he said.

Data from external surveys indicates a growing prevalence of GLP-1 medication use among the population. A July Gallup poll found that 11% of U.S. adults are currently on a GLP-1 medication. The share of U.S. adults on GLP-1 medication is nearly four times the share from two years prior to the July Gallup poll.

These medications have been associated with changes in eating behaviors, including reduced frequency of restaurant visits. A survey by the National Restaurant Association found that nearly half of GLP-1 users said they had cut back on dining out since beginning the medications.

Specific food categories appear to be affected by these dietary shifts. An April survey of 300 GLP-1 users by William Blair found that 72% were specifically cutting back on hamburgers.

Financial analysts have projected potential long-term economic effects on the food and beverage sector. JPMorgan estimated in February that the rise of GLP-1s could erase between $30 billion and $55 billion in annual revenue for the food and beverage industry by as early as 2030.

Access to these medications may expand further through federal initiatives. The federal government is piloting a program aimed at increasing access to GLP-1s for Medicare enrollees.

King has undertaken significant operational changes in recent years through a strategy called 'Reclaim the Flame.' The company has invested over $2 billion into branding, remodeling restaurants, and upgrading menu offerings.

Recent financial performance shows a rebound in U.S. sales figures. King U.S. saw a 5.8% increase in comparable store sales in the first quarter of the year. This growth follows a period of decline, as King U.S. experienced a 1.1% drop in comparable store sales in the first quarter of the previous year.

King's approach balances preparation for these changes with a commitment to its core business model. The company is monitoring demand before making permanent menu changes, citing the importance of operational simplicity. Recent sales growth suggests that current strategies are yielding positive results despite the evolving landscape.